196 related articles for article (PubMed ID: 18221217)
1. Glutamatergic dysfunction--newer targets for anti-obsessional drugs.
Bhattacharyya S; Chakraborty K
Recent Pat CNS Drug Discov; 2007 Jan; 2(1):47-55. PubMed ID: 18221217
[TBL] [Abstract][Full Text] [Related]
2. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
Pittenger C; Krystal JH; Coric V
NeuroRx; 2006 Jan; 3(1):69-81. PubMed ID: 16490414
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
[TBL] [Abstract][Full Text] [Related]
4. The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD.
Marazziti D; Albert U; Mucci F; Piccinni A
Curr Med Chem; 2018; 25(41):5731-5738. PubMed ID: 29119912
[TBL] [Abstract][Full Text] [Related]
5. Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
Vlček P; Polák J; Brunovský M; Horáček J
Pharmacopsychiatry; 2018 Nov; 51(6):229-242. PubMed ID: 28950396
[TBL] [Abstract][Full Text] [Related]
6. A review of animal models of obsessive-compulsive disorder: a focus on developmental, immune, endocrine and behavioral models.
Grados M; Prazak M; Saif A; Halls A
Expert Opin Drug Discov; 2016; 11(1):27-43. PubMed ID: 26558411
[TBL] [Abstract][Full Text] [Related]
7. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.
Pittenger C; Bloch MH; Williams K
Pharmacol Ther; 2011 Dec; 132(3):314-32. PubMed ID: 21963369
[TBL] [Abstract][Full Text] [Related]
8. Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings.
Nakao T; Okada K; Kanba S
Psychiatry Clin Neurosci; 2014 Aug; 68(8):587-605. PubMed ID: 24762196
[TBL] [Abstract][Full Text] [Related]
9. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder.
Delgado PL; Moreno FA
Br J Psychiatry Suppl; 1998; (35):21-5. PubMed ID: 9829023
[TBL] [Abstract][Full Text] [Related]
10. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
Marinova Z; Chuang DM; Fineberg N
Curr Neuropharmacol; 2017; 15(7):977-995. PubMed ID: 28322166
[TBL] [Abstract][Full Text] [Related]
11. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.
Moore GJ; MacMaster FP; Stewart C; Rosenberg DR
J Am Acad Child Adolesc Psychiatry; 1998 Jun; 37(6):663-7. PubMed ID: 9628087
[TBL] [Abstract][Full Text] [Related]
12. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Nakamae T
Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
Okamoto Y
Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
[TBL] [Abstract][Full Text] [Related]
14. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
[TBL] [Abstract][Full Text] [Related]
15. Obsessive compulsive disorder and the glutamatergic system.
Kariuki-Nyuthe C; Gomez-Mancilla B; Stein DJ
Curr Opin Psychiatry; 2014 Jan; 27(1):32-7. PubMed ID: 24270485
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of obsessive compulsive disorder.
Goodman WK; McDougle CJ; Price LH
J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic Strategies and New Targets in OCD.
Pittenger C
Curr Top Behav Neurosci; 2021; 49():331-384. PubMed ID: 33751503
[TBL] [Abstract][Full Text] [Related]
18. The right thalamic glutamate level correlates with functional connectivity with right dorsal anterior cingulate cortex/middle occipital gyrus in unmedicated obsessive-compulsive disorder: A combined fMRI and
Chen Y; Meng Z; Zhang Z; Zhu Y; Gao R; Cao X; Tan L; Wang Z; Zhang H; Li Y; Fan Q
Aust N Z J Psychiatry; 2019 Mar; 53(3):207-218. PubMed ID: 30354192
[TBL] [Abstract][Full Text] [Related]
19. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
Korff S; Harvey BH
Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
[TBL] [Abstract][Full Text] [Related]
20. [Significance of the glutaminergic system for obsessive-compulsive disorder].
Nissen JB; Thomsen PH
Ugeskr Laeger; 2008 Sep; 170(37):2874-6. PubMed ID: 18796282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
